- Condition: End-stage Renal Disease
Interventions: Device: Heparin-bonded vascular access graft; Device: Conventional ePTFE hemodialysis graft
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Not yet recruiting - verified May 2012 - Condition: Cataract
Interventions: Drug: 40 mg/mL Dexamethasone phosphate ophthalmic solution; Drug: 100 mM sodium citrate buffer solution
Sponsors: Eyegate Pharmaceuticals, Inc.; Eyegate Pharmaceuticals, Inc.
Not yet recruiting - verified May 2012 - Condition: Healthy Volunteers
Interventions: Drug: Warfarin; Drug: Dexpramipexole
Sponsors: Biogen Idec; Biogen Idec
Not yet recruiting - verified May 2012 - Condition: Focus of Study: Pharmacokinetics of Enoxaparin in Obese Children
Intervention:
Sponsors: Children's Research Institute; Children's Research Institute
Recruiting - verified May 2012 - Conditions: Cardiopulmonary Bypass; Altered Heparin Response
Interventions: Drug: Heparin; Drug: ATryn
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; GTC Biotherapeutics
Not yet recruiting - verified May 2012 - Condition: Venous Thromboembolism (VTE)
Interventions: Drug: Betrixaban; Drug: Enoxaparin
Sponsors: Portola Pharmaceuticals; Portola Pharmaceuticals
Recruiting - verified April 2012 - Conditions: End Stage Renal Disease; Kidney Failure; Renal Failure; Hyperphosphatemia; ESRD
Intervention: Drug: ferric citrate
Sponsors: Keryx Biopharmaceuticals; Keryx Biopharmaceuticals
Not yet recruiting - verified March 2012 - Condition: Atrial Fibrillation
Intervention: Drug: Dabigatran etexilate (Pradaxa)
Sponsors: University of Utah; University of Utah
Recruiting - verified March 2012 - Conditions: Secondary Hypogonadism; Low Testosterone
Interventions: Drug: enclomiphene citrate; Drug: Testosterone
Sponsors: Repros Therapeutics Inc.; Repros Therapeutics Inc.
Not yet recruiting - verified April 2012 - Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: dalteparin; Drug: lenalidomide; Drug: dexamethasone; Other: laboratory biomarker analysis
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI); Celgene Corporation
Recruiting - verified January 2012 - Conditions: Osteoarthritis of the Knee; Coagulopathy
Intervention: Drug: PENNSAID (diclofenac sodium solution topical)
Sponsors: Arthritis Treatment Center, Maryland; Nathan Wei, MD, FACP, FACR:; Covidien; Arthritis Treatment Center, Maryland
Recruiting - verified February 2012 - Condition: Anterior Uveitis
Interventions: Drug: 40 mg/mL Dexamethasone phosphate ophthalmic solution; Drug: Prednisolone Acetate (1%) Eyedrops; Drug: 100 mM sodium citrate buffer solution; Drug: Placebo Eyedrops
Sponsors: Eyegate Pharmaceuticals, Inc.; Eyegate Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Solid Tumors
Interventions: Drug: tivantinib; Drug: omeprazole; Drug: s-warfarin; Drug: caffeine; Dietary Supplement: vitamin K; Drug: digoxin; Drug: midazolam
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; Medpace, Inc.
Recruiting - verified January 2012 - Conditions: Obesity; Leptin Resistance
Interventions: Drug: Saline; Drug: Intralipid; Dietary Supplement: Water; Dietary Supplement: Soybean oil; Drug: Heparin
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center
Recruiting - verified January 2012 - Conditions: Gestational Diabetes; Obesity
Interventions: Dietary Supplement: Magnesium citrate; Dietary Supplement: Placebo; Behavioral: Dietary modification
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified January 2012 - Condition: Infection; Dialysis Catheter
Interventions: Drug: NAC/Tigecycline/Heparin combination lock solution; Drug: Standard anticoagulant (Heparin or Citrate)
Sponsors: University of California, San Diego; University of California, San Diego
Not yet recruiting - verified November 2011 - Condition: Coagulation Delay
Interventions: Dietary Supplement: phytonadione; Drug: none-control group
Sponsors: James A. Haley Veterans Administration Hospital; James A. Haley Veterans Administration Hospital
Recruiting - verified December 2011 - Condition: Central Line-Associated Bloodstream Infection
Interventions: Drug: ethanol; Drug: heparin-saline placebo
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012 - Condition: Venous Thromboembolism
Intervention: Drug: Fondaparinux
Sponsors: Wayne State University; Wayne State University; GlaxoSmithKline
Not yet recruiting - verified November 2011 - Condition: Ischemic Stroke
Interventions: Drug: Argatroban; Drug: Argatroban
Sponsors: The University of Texas Health Science Center, Houston; Andrew Barreto
Recruiting - verified November 2011 - Conditions: Keratoconus; Corneal Ectasia
Interventions: Drug: Riboflavin; Drug: Riboflavin
Sponsors: Cornea and Laser Eye Institute; Cornea and Laser Eye Institute
Recruiting - verified November 2011 - Condition: Coronary Artery Disease
Interventions: Drug: Bivalirudin; Drug: Heparin
Sponsors: Stony Brook University; Stony Brook University
Recruiting - verified October 2011 - Condition: Metastatic Pancreatic Cancer
Interventions: Drug: Abraxane ( Nab-paclitaxel); Drug: Abraxane ( Nab-paclitaxel); Drug: Gemcitabine; Drug: Gemcitabine; Drug: ODSH ( 2-O, 3-O Desulfated Heparin); Drug: ODSH ( 2-O, 3-O Desulfated Heparin); Drug: Abraxane ( nab-paclitaxel); Drug: Gemcitabine
Sponsors: ParinGenix; ParinGenix; TGen Drug Development Services
Recruiting - verified April 2012 - Conditions: Sickle Cell Disease; Vaso-occlusive Crisis
Interventions: Drug: Placebo; Drug: Dalteparin
Sponsors: Duke University; Duke University; Eisai Limited
Recruiting - verified August 2011 - Condition: Venous Thrombosis
Intervention: Device: Gore Viabahn Heparin Coated Stent
Sponsors: Stanford University; Stanford University
Recruiting - verified July 2011 - Condition: Arthritis
Intervention: Drug: sodium citrate and citric acid
Sponsors: Texas Tech University Health Sciences Center; Texas Tech University Health Sciences Center
Recruiting - verified August 2011 - Conditions: Obesity; Morbid Obesity; Venous Thromboembolism; Atrial Fibrillation; Angina; Chest Pain
Intervention: Drug: Lean Body Weight-based heparin dose
Sponsors: Nazareth Hospital; Nazareth Hospital
Recruiting - verified August 2011 - Conditions: Drug Interactions; BRAF; Cancer
Interventions: Drug: Warfarin; Drug: Ketoconazole; Drug: Gemfibrozil; Drug: GSK2118436 150mg; Drug: GSK2118436 75mg
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Solid Tumor; Hematological Malignancy
Intervention: Drug: Belinostat, Warfarin
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; TopoTarget A/S
Recruiting - verified March 2011 - Condition: Warfarin Initiation
Intervention: Device: Warfarin GenoSTAT Test
Sponsors: Iverson Genetic Diagnostics, Inc.; Iverson Genetic Diagnostics, Inc.
Recruiting - verified January 2012 - Conditions: Venous Thromboembolism; Postpartum
Interventions: Drug: Dalteparin Sodium; Drug: 0.9% Bacteriostatic Sodium Chloride
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Canadian Institutes of Health Research (CIHR)
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: systemic chemotherapy; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: AML; ALL; CML in Blast Crisis; High-Risk MDS; Multiple Myeloma
Intervention: Drug: TG02 citrate
Sponsors: Tragara Pharmaceuticals, Inc.; Tragara Pharmaceuticals, Inc.
Recruiting - verified December 2011 - Conditions: Atrial Fibrillation; Stroke
Interventions: Device: WATCHMAN Device; Drug: Warfarin
Sponsors: Atritech; Atritech
Recruiting - verified April 2012 - Conditions: Keratoconus; Corneal Ectasia
Interventions: Drug: Riboflavin/Dextran; Drug: Hypotonic Riboflavin
Sponsors: Cornea and Laser Eye Institute; Cornea and Laser Eye Institute
Recruiting - verified November 2011 - Condition: Postoperative Hemorrhage
Interventions: Drug: Antithrombin (Recombinant); Other: Placebo
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; Children's Research Institute; GTC Biotherapeutics
Recruiting - verified November 2011 - Condition: Renal Insufficiency
Intervention: Drug: fondaparinux sodium injection
Sponsors: Duke University; Duke University; GlaxoSmithKline
Recruiting - verified August 2011 - Condition: Severe Congenital Protein C Deficiency
Intervention: Biological: Protein C Concentrate (Human)
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation; American Thrombosis and Hemostasis Network; UDC Rare Bleeding and Clotting Disorders Working Group (RBDWG)
Recruiting - verified September 2011 - Condition: Acute Coronary Syndrome
Interventions: Drug: Otamixaban (XRP0673); Drug: Otamixaban matching placebo; Drug: Unfractionated Heparin; Drug: Unfractionated Heparin matching placebo; Drug: Eptifibatide; Drug: Eptifibatide matching placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Renal Cell Carcinoma
Intervention: Drug: Sunitinib and Dalteparin mono and combination therapy
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; Pfizer
Recruiting - verified March 2012 - Condition: Pulmonary Hypertension
Intervention: Drug: Warfarin
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011 - Condition: Deep Venous Thrombosis
Intervention: Drug: Low-Molecular-Weight Heparin
Sponsors: University of Tennessee; University of Tennessee
Recruiting - verified June 2011 - Condition: Thromboembolism
Interventions: Other: Pharmacogenetic Warfarin Initiation; Other: Clinical Warfarin Initiation (non-pharmacogenetic); Other: Pharmacogenetic Warfarin Initiation; Other: Clinical Warfarin Initiation (non-pharmacogenetic)
Sponsors: Washington University School of Medicine; Washington University School of Medicine; Intermountain Health Care, Inc.; University of Utah; Hospital for Special Surgery, New York; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2011 - Conditions: Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism; Thromboembolism; Venous Thrombosis
Interventions: Drug: edoxaban tosylate(DU-176b); Drug: low molecular weight heparin/unfractionated heparin; Drug: warfarin
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified February 2012 - Condition: Idiopathic Venous Thromboembolism
Intervention: Other: Application of the"Men continue and HER DOO2" rule
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Biomerieux
Recruiting - verified July 2011 - Conditions: Pancreatic Cancer; Venous Thromboembolism
Intervention: Drug: Dalteparin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Eisai Inc.
Recruiting - verified February 2012 - Condition: Venous Thromboembolism
Intervention: Drug: Fragmin
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Conditions: Pregnancy; Thrombophilia; Pregnancy Complications
Interventions: Drug: dalteparin sodium 5,000 IU prefilled syringes (antenatal); Drug: dalteparin sodium (after delivery - Control group)
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Canadian Institutes of Health Research (CIHR)
Recruiting - verified July 2011 - Conditions: Atrial Fibrillation; Deep Vein Thrombosis; Dilated Cardiomyopathies
Interventions: Behavioral: Financial Incentive and Med-eMonitor; Device: 2Med-eMonitor
Sponsors: University of Pennsylvania; University of Pennsylvania
Recruiting - verified August 2011 - Conditions: Atrial Fibrillation; Deep Vein Thrombosis; Pulmonary Embolism; Artificial Heart Valve
Interventions: Other: Genotype-guided dose determination; Other: Non-genotype guided warfarin dosing
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; UNC Institute for Pharmacogenomics and Individualized Therapy
Recruiting - verified February 2012 - Conditions: Stroke; Transient Ischemic Attack
Interventions: Drug: Antithrombotic treatment; Device: percutaneous device closure of PFO
Sponsors: University Hospital Inselspital, Berne; University Hospital Inselspital, Berne; University Hospital, Basel, Switzerland; University of Lausanne Hospitals; University Hospital, Geneva; University Hospital, Zürich; Triemli Hospital; Cantonal Hospital of Aarau, Switzerland; Alfried-Krupp Krankenhaus of Essen, Germany; University Hospital, Essen; Klinikum Worms gGmbH, Germany; Tufts Medical Center; Baystate Medical Center; East Medical Center Tyler, Texas; Universitaire Ziekenhuizen Leuven
Recruiting - verified January 2012 - Conditions: Stroke; Venous Thrombosis; Atrial Fibrillation; Atrial Flutter
Interventions: Behavioral: Genotype-guided dosing algorithm for warfarin; Behavioral: Clinical-guided dosing algorithm for warfarin
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Bristol-Myers Squibb
Recruiting - verified May 2012 - Condition: Deep Venous Thrombosis
Intervention: Drug: Bivalirudin
Sponsors: Children's Hospital Los Angeles; Children's Hospital Los Angeles; Texas Children's Hospital; Children's Hospital Colorad; Children's Hospital of Philadelphia; Nationwide Children's Hospital; University of Texas Southwestern Medical Center
Recruiting - verified May 2011 - Condition: Carotid Artery Disease
Intervention: Device: RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System
Sponsors: Medstar Research Institute; Medstar Research Institute
Recruiting - verified April 2012 - Condition: Reversal of Coagulopathy
Interventions: Biological: Beriplex® P/N; Biological: Fresh frozen plasma
Sponsors: CSL Behring; CSL Behring
Recruiting - verified May 2012 - Condition: Venous Thromboembolism
Intervention:
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Heart and Stroke Foundation of Ontario
Recruiting - verified June 2011 - Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); Bacchus Vascular; BSN Medical Inc; Genentech; MEDRAD Interventional/Possis; Mid America Heart Institute; Society of Interventional Radiology Foundation; Massachusetts General Hospital
Recruiting - verified May 2012 - Condition: Neonatal Anemia
Interventions: Biological: Transfused Biotin RBCs - Adults Phase I; Biological: Transfused Biotin RBCs - Infants Phase II; Biological: Transfused Biotin RBCs - Infants Phase III
Sponsors: University of Iowa; University of Iowa; National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI); Thrasher Research Fund
Recruiting - verified February 2012 - Condition: Venous Thrombosis
Interventions: Drug: Enoxaparin; Drug: warfarin; Drug: Placebo for apixaban; Drug: Placebo for enoxaparin; Drug: Placebo for warfarin; Drug: apixaban
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Recruiting - verified October 2010 - Condition: Hepatic Veno-Occlusive Disease
Intervention: Drug: Defibrotide
Sponsors: Gentium SpA; Gentium SpA
Recruiting - verified May 2012 - Conditions: Non-Small Cell Lung Cancer; Venous Thromboembolism
Intervention: Drug: Carboplatin, Paclitaxel, Arixtra
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified July 2011 - Condition: Antithrombin III Deficiency
Intervention: Drug: Plasma-derived AT-III concentrate
Sponsors: Grifols Biologicals Inc.; Grifols Biologicals Inc.
Recruiting - verified March 2012 - Condition: Heart Valve Disease
Interventions: Device: On-X valve using reduced anticoagulation; Device: On-X Valve with Standard Coumadin Therapy
Sponsors: Medical Carbon Research Institute, LLC; Medical Carbon Research Institute, LLC
Recruiting - verified June 2011 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Sildenafil citrate; Drug: Sildenafil citrate; Drug: Sildenafil citrate
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
 |
Anticoagulants Clinical Trials |
